The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
 
Yuko Takahashi
Research Funding - MSD
 
Shinsuke Sasada
No Relationships to Disclose
 
Naoto Kondo
No Relationships to Disclose
 
Hiroya Hashimoto
No Relationships to Disclose
 
Kaori Terata
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichikyo; Pfizer
 
Yasuaki Sagara
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Japan; Eisai; Lilly; MSD; Pfizer
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Kumiko Kida
Speakers' Bureau - AstraZeneca; Chugai Pharma; Taiho Pharmaceutical
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
Research Funding - Lilly Japan (Inst)
 
Keisei Anan
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Akihiko Suto
No Relationships to Disclose
 
Chizuko Kanbayashi
No Relationships to Disclose
 
Mina Takahashi
No Relationships to Disclose
 
Rikiya Nakamura
No Relationships to Disclose
 
Toshiyuki Ishiba
No Relationships to Disclose
 
Michiko Tsuneizumi
No Relationships to Disclose
 
Seiichiro Nishimura
No Relationships to Disclose
 
Fumikata Hara
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)